Can you discuss your clinical practice and research focus?

The patients that you see, are they mostly referrals? And of your patients, what percentage would you say are chronic vs episodic?

Can you discuss what the current treatment paradigm might look like nowadays for abortive agents? Is it mostly over the counter NSAIDs, triptans, then CGRPs? Where does botox and IHE fit in there?

Is it generally fair to say that patients with episodic migraine are more likely to just use abortive agents, where as chronic migraine patients are more likely to use both preventative and abortive agents?

For patients who take Nurtec ODT,  how common do you think it is that patients are taking Nurtec for both abortive and preventative use? Or is it more likely patients taking medications for both abortive and preventative use would take different classes of drugs respectively?

How has your experience with insurance coverage with CGRPs been? Have you noticed any significant differences in coverage between the SC and oral agents?

Looking at the preventative SC CGRP agents, do you have a preference? Emgality doesn't have dosing flexibility, but is also indicated for cluster headache. Aimovig has two different monthly doses and Ajovy has monthly and quarterly dosing flexibility. Do those play into your decisions at all? Do you find these differences particularly meaningful for patients?

for your patients currently on injectable CGRPs, how many would you say are episodic vs chronic?

Have you prescribed Qulipta yet? For people on preventative CGRPs, how many would you say are using any injectable CGRPs vs Nurtec ODT or Qulipta?

The data from Nurtec on the preventative indication doesn't seem very strong. Of your patients who are taking Nurtec for preventative use, how many would you estimate report no significant change in monthly migraines?

Looking at Vyepti, the IV CGRP, it seems to have similar efficacy as the SC agents. Is it fair to say that this isn't a very popular choice due to the downsides of logistics and convenience?

It seems like Ubrelvy has more dosing flexibility, where you can redone if the first dose doesn't abort the migraine, but patients might like the ODT formulation of Nurtec, maybe increased tolerability for patients with severe nausea or vomiting. Do you or your patients have a preference for Ubrelvy or Nurtec? Are there any other key differences between the two which are significant for patients?

Of your patients currently on Nurtec, what percentage do you think are taking it in an abortive context vs a preventative one?

So the CGRP space is dominated by big Pharma, but BioHaven has managed to do quite well versus the much bigger competition. Do you have any big theories as to why that is? Maybe analgesic rebound?

Are you familiar with their intranasal CGRP, I think it's called zavegepant? Besides efficacy, what do you think would be the key considerations for an intranasal CGRP wrt market adoption?